Galapagos - GLPG Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year price targets for Galapagos' shares. Their GLPG share price forecasts range from $40.00 to $70.00. On average, they predict the company's share price to reach $49.17 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts.

Galapagos' stock was trading at $44.38 on January 1st, 2023. Since then, GLPG stock has decreased by 15.4% and is now trading at $37.55.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our GLPG earnings forecast.

ETFs with the largest weight of Galapagos (NASDAQ:GLPG) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), ERShares NextGen Entrepreneurs ETF (ERSX), BlackRock Future Health ETF (BMED), iShares Biotechnology ETF (IBB), Dimensional International Small Cap ETF (DFIS), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos' stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (5.67%), Finepoint Capital LP (0.59%), Renaissance Technologies LLC (0.51%), Stonepine Capital Management LLC (0.30%), Price T Rowe Associates Inc. MD (0.19%) and Morgan Stanley (0.18%).

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLPG stock can currently be purchased for approximately $37.55.

Galapagos (NASDAQ:GLPG) has a market capitalization of $2.47 billion and generates $532.48 million in revenue each year. The biotechnology company earns $-229,730,000.00 in net income (profit) each year or ($3.43) on an earnings per share basis.

The company employs 1,309 workers across the globe.

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901.